Deliver Your News to the World

News

Distribute Your News

  • Every day, hundreds of individuals and companies choose WebWire to distribute their news.
  • WebWire places your news within numerous highly trafficked news search engines generating leads and publicity.
  • Submit Your Release Now!

Medical / Pharmaceuticals

Releases published in the last 30 days. RSS 0.91 Feed

Page 1 of 5

HIVMA Urges Senate Not to Proceed with Affordable Care Act Repeal
HIVMA Urges Senate Not to Proceed with Affordable Care Act Repeal
7/26/2017 8:45:58 AM
The HIV Medicine Association urges our senators to stand up for the health of millions of Americans, including the 1.2 million living with HIV in the United States, by rejecting the Motion to Proceed with a vote on either the Better Care Reconciliation Act or the Obamacare Repeal Reconciliation Act.
Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent
Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent
7/25/2017 12:16:39 PM
Abbott today announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a XIENCE everolimus-eluting coronary stent.  The study, called XIENCE Short DAPT, will evaluate if three months of DAPT is non-inferior to the current standard of 12 …
ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings
ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings
7/25/2017 12:04:56 PM
ViiV Healthcare, the global specialist HIV company, majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive interim results from DAWNING.
ZEISS Opts for Continuity: CEO Kaschke confirmed until 2020
ZEISS Opts for Continuity: CEO Kaschke confirmed until 2020
7/25/2017 11:28:04 AM
The Supervisory Board of Carl Zeiss AG has decided to continue the appointment of Dr. Michael Kaschke as President & CEO until 30 June 2020. Kaschke joined the ZEISS Group 25 years ago and has served on the Executive Board since 2000.
Johnson & Johnson Announces Encouraging First-in-Human Clinical Data for Investigational HIV Preventive Vaccine
Johnson & Johnson Announces Encouraging First-in-Human Clinical Data for Investigational HIV Preventive Vaccine
7/25/2017 10:20:19 AM
Johnson & Johnson announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Companies.
Evolution of pregnancy may be key to better reproductive technologies today
Evolution of pregnancy may be key to better reproductive technologies today
7/25/2017 10:11:35 AM
Pregnancy in humans has typically been studied as an anti-inflammatory process, where a mother’s immune system is suppressed to protect the fetus from attack.
Elsevier updates “Bretherick’s Handbook of Reactive Chemical Hazards“
Elsevier updates “Bretherick’s Handbook of Reactive Chemical Hazards“
7/25/2017 10:03:48 AM
Elsevier, the information analytics company specializing in science and health, announced the publication of the eighth edition of Bretherick’s Handbook of Reactive Chemical Hazards, edited by Peter G.
HealthCombix Expands Healthcare Blockchain Advisory Team
HealthCombix Expands Healthcare Blockchain Advisory Team
7/25/2017 10:00:00 AM
HealthCombix, a global decentralized healthcare blockchain network development company, announced today both Dr. Andreas Freund, PhD and Mr. Peter Nichol have joined the company Advisory Board.
GSK submits US regulatory filing of Arnuity Ellipta in children with asthma
GSK submits US regulatory filing of Arnuity Ellipta in children with asthma
7/24/2017 4:03:42 PM
Arnuity Ellipta (fluticasone furoate 100mcg and 200mcg) is an inhaled corticosteroid (ICS) which was approved in the US in August 2014 for the maintenance treatment of asthma in patients aged 12 years and older.
Pfizer Announces Positive Top-Line Results from The Comparative Reflections B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin®1 (bevacizumab)
Pfizer Announces Positive Top-Line Results from The Comparative Reflections B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin®1 (bevacizumab)
7/24/2017 3:11:20 PM
Pfizer Inc. (NYSE:PFE) today announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin® (bevacizumab), met its primary objective.
Data Published in The Lancet Shows High Efficacy at 96 Weeks for First Investigational Two-Drug, Long-Acting Injectable HIV Regimen
Data Published in The Lancet Shows High Efficacy at 96 Weeks for First Investigational Two-Drug, Long-Acting Injectable HIV Regimen
7/24/2017 12:34:00 PM
Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced that a regimen of two investigational long-acting, injectable formulations of HIV medicines —Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir — given together every 4 or 8 weeks was as effective as 3-drug oral antiretroviral therapy (ART) at …
Philips’ Second Quarter Results 2017
Philips’ Second Quarter Results 2017
7/24/2017 8:47:50 AM
Second-quarter highlights • Sales increased to EUR 4.3 billion, with comparable sales growth of 4%; comparable order intake increased 8% compared to Q2 2016 • Net income from continuing operations amounted to EUR 161 million, compared to EUR 118 million in Q2 2016 • Adjusted EBITA improved 15% to EUR 439 million, or 10.2% of sales, compared to EUR 383 million, or …
EMA’s CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA’s CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
7/24/2017 7:37:46 AM
Merck KGaA, Darmstadt,  Germany, which operates its biopharmaceutical business as EMD Serono in the US and  Canada, and Pfizer Inc. (NYSE:  PFE ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of avelumab* (BAVENCIO ® ) as a monotherapy for the treatment of adult patients …
COX-2 Inhibitors May Reverse IDO1-mediated Immunosuppression in Some Cancers
COX-2 Inhibitors May Reverse IDO1-mediated Immunosuppression in Some Cancers
7/21/2017 8:40:10 PM
In preclinical studies, tumors that consitutively expressed the protein indoleamine 2,3-dioxygenase (IDO1) responded to the cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex) and had improved infiltration of certain subsets of T cells, making them more likely to respond to anti-PD1 therapies, according to data published in Cancer Immunology Research, a journal of the …
Small Survey: Most Primary Care Physicians Can’t Identify All Risk Factors for Prediabetes
Small Survey: Most Primary Care Physicians Can’t Identify All Risk Factors for Prediabetes
7/21/2017 6:32:31 PM
Johns Hopkins researchers who distributed a survey at a retreat and medical update for primary care physicians (PCPs) report that the vast majority of the 140 doctors who responded could not identify all 11 risk factors that experts say qualify patients for prediabetes screening.
GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination
GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination
7/21/2017 1:32:48 PM
FF/VI is currently indicated in Europe for the regular treatment of patients aged 12 and over with asthma who are not adequately controlled on both ICS and ’as-needed’ short-acting β2-agonist (SABA) and where use of a combination product (ICS and LABA) is appropriate.
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
7/21/2017 12:45:59 PM
  Sanofi  and  Regeneron Pharmaceuticals, Inc.  today announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Dupixent® (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis  who are candidates for systemic …
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis
7/21/2017 12:27:19 PM
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Actemra®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition.
Merck and Pfizer Collaborate with Corning
Merck and Pfizer Collaborate with Corning
7/21/2017 6:59:42 AM
Merck (NYSE: MRK), Pfizer (NYSE: PFE) and Corning Incorporated (NYSE: GLW) today announced collaborations that have enabled the modernization of pharmaceutical packaging with the introduction of Corning Valor™ Glass.
FDA clears first neonatal magnetic resonance imaging device
FDA clears first neonatal magnetic resonance imaging device
7/20/2017 2:11:01 PM
Today, the U.S. Food and Drug Administration cleared the first magnetic resonance imaging (MRI) device specifically for neonatal brain and head imaging in neonatal intensive care units (NICU).